Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Abstract

In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.).

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• St. Michael's Hospital CA
• Université Paris Cité FR
• Assistance Publique – Hôpitaux de Paris FR
• Women's College Hospital CA
• Yale University US
• University Health Network CA
• Instituto Cardiovascular de Rosario AR
• University of Toronto CA
• Aston University GB
• Duke University US
• State University of New York US
• Saint Luke's Hospital US
• University of Missouri–Kansas City US
• SUNY Downstate Health Sciences University US
• Clinical Research Institute US
• Inserm FR
• University of Michigan US
• Imperial College London GB
• Hôpital Bichat-Claude-Bernard FR
• The University of Texas Southwestern Medical Center US
• Oregon Health & Science University US
• Vanderbilt University Medical Center US
• Estudios Clínicos Latinoamérica AR
• University of Colorado Anschutz Medical Campus US
• Parkland Health & Hospital System US
• Lexicon Pharmaceuticals (United States) US

Related Publications